Caliway Biopharmaceuticals Co Ltd banner
C

Caliway Biopharmaceuticals Co Ltd
TWSE:6919

Watchlist Manager
Caliway Biopharmaceuticals Co Ltd
TWSE:6919
Watchlist
Price: 85.6 TWD -6.75% Market Closed
Market Cap: NT$133B

Multiples-Based Value

The Multiples-Based Value of one Caliway Biopharmaceuticals Co Ltd stock under the Base Case scenario is 0.44 TWD. Compared to the current market price of 85.6 TWD, Caliway Biopharmaceuticals Co Ltd is Overvalued by 99%.

Multiples-Based Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

Multiples-Based Value
Base Case
0.44 TWD
Overvaluation 99%
Multiples-Based Value
Price
C
Worst Case
Base Case
Best Case

Multiples Across Competitors

Competitors Multiples
Caliway Biopharmaceuticals Co Ltd Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
All Countries
Close
Market Cap P/S P/E EV/EBITDA EV/EBIT
TW
Caliway Biopharmaceuticals Co Ltd
TWSE:6919
132.9B TWD 3 494.9 -377.7 -189.3 -181.1
US
Eli Lilly and Co
NYSE:LLY
829.8B USD 12.7 40.2 27.2 29
US
Johnson & Johnson
NYSE:JNJ
579B USD 6.1 21.6 15 18.4
CH
Roche Holding AG
SIX:ROG
248.4B CHF 4 19.3 11.5 12.9
US
Merck & Co Inc
NYSE:MRK
296B USD 4.6 16.2 10 12.2
CH
Novartis AG
SIX:NOVN
229.3B CHF 5.2 21.1 13 16.8
UK
AstraZeneca PLC
LSE:AZN
214.5B GBP 5.1 29.1 16.1 22.7
IE
Endo International PLC
LSE:0Y5F
237.1B USD 102.3 -81.1 375.3 941.3
DK
Novo Nordisk A/S
CSE:NOVO B
1T DKK 3.3 9.8 7.3 8.6
US
Pfizer Inc
NYSE:PFE
153.7B USD 2.5 19.8 7.6 10.2
US
Bristol-Myers Squibb Co
NYSE:BMY
117.8B USD 2.4 16.7 7.1 8.7
P/E Multiple
Earnings Growth PEG
TW
C
Caliway Biopharmaceuticals Co Ltd
TWSE:6919
Average P/E: 21.5
Negative Multiple: -377.7
N/A N/A
US
Eli Lilly and Co
NYSE:LLY
40.2
32%
1.3
US
Johnson & Johnson
NYSE:JNJ
21.6
7%
3.1
CH
Roche Holding AG
SIX:ROG
19.3
14%
1.4
US
Merck & Co Inc
NYSE:MRK
16.2
14%
1.2
CH
Novartis AG
SIX:NOVN
21.1
14%
1.5
UK
AstraZeneca PLC
LSE:AZN
29.1
26%
1.1
IE
E
Endo International PLC
LSE:0Y5F
Negative Multiple: -81.1 N/A N/A
DK
Novo Nordisk A/S
CSE:NOVO B
9.8
1%
9.8
US
Pfizer Inc
NYSE:PFE
19.8
22%
0.9
US
Bristol-Myers Squibb Co
NYSE:BMY
16.7
16%
1
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
TW
C
Caliway Biopharmaceuticals Co Ltd
TWSE:6919
Average EV/EBITDA: 49
Negative Multiple: -189.3
N/A N/A
US
Eli Lilly and Co
NYSE:LLY
27.2
22%
1.2
US
Johnson & Johnson
NYSE:JNJ
15
2%
7.5
CH
Roche Holding AG
SIX:ROG
11.5
6%
1.9
US
Merck & Co Inc
NYSE:MRK
10
3%
3.3
CH
Novartis AG
SIX:NOVN
13
5%
2.6
UK
AstraZeneca PLC
LSE:AZN
16.1
13%
1.2
IE
E
Endo International PLC
LSE:0Y5F
375.3
N/A N/A
DK
Novo Nordisk A/S
CSE:NOVO B
7.3
1%
7.3
US
Pfizer Inc
NYSE:PFE
7.6
-9%
N/A
US
Bristol-Myers Squibb Co
NYSE:BMY
7.1
-10%
N/A
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
TW
C
Caliway Biopharmaceuticals Co Ltd
TWSE:6919
Average EV/EBIT: 108.1
Negative Multiple: -181.1
N/A N/A
US
Eli Lilly and Co
NYSE:LLY
29
22%
1.3
US
Johnson & Johnson
NYSE:JNJ
18.4
6%
3.1
CH
Roche Holding AG
SIX:ROG
12.9
6%
2.2
US
Merck & Co Inc
NYSE:MRK
12.2
6%
2
CH
Novartis AG
SIX:NOVN
16.8
9%
1.9
UK
AstraZeneca PLC
LSE:AZN
22.7
21%
1.1
IE
E
Endo International PLC
LSE:0Y5F
941.3
N/A N/A
DK
Novo Nordisk A/S
CSE:NOVO B
8.6
2%
4.3
US
Pfizer Inc
NYSE:PFE
10.2
-4%
N/A
US
Bristol-Myers Squibb Co
NYSE:BMY
8.7
-7%
N/A
Get AI-powered insights for any company or topic.
Open AI Assistant

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett